So prior to Cobenfy, what drugs were doing was treating the symptoms ... We continue to take decisive action to further right size our cost structure and invest in future growth.

The firm’s Cobenfy drug for schizophrenia is the first of its ... in capital expenditures in 2024 to build a data center the size of Manhattan. Overall, Meta Platforms, Inc (NASDAQ:META ...

Top stock picks for capital appreciation and outperformance, with a focus on profits, dividends, and long-term viability.

Therefore, its track record of successful drug development and commercialization ... of Bristol-Myers Squibb Company (NYSE:BMY)’s COBENFY, which continues to demonstrate strong sales momentum ...

Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

Cobenfy comes as a capsule. It received Food and Drug Administration approval on Sept. 26 as a treatment for schizophrenia, then launched onto the U.S. market in late October. By Bristol Myers ...

Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of ...

The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex Pharmaceuticals. The drug, which is called suzetrigine and will be sold under ...

Colombian President Gustavo Petro has said that “cocaine is no worse than whiskey” as he suggested the global cocaine industry could be “easily dismantled” if the drug was legalized worldwide.

According to Cramer “The only stuff I would think about buying are the drugs, medical device. Because their business, for the most part, not made in China, not made in Mexico. So those are the ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...